TABLE 2.
Study, Year | Asfar et al (27) | Lamontagne et al (28) | Lamontagne et al (4) | |||
---|---|---|---|---|---|---|
Randomized Group | Lower MAP Target | Higher MAP Target | Lower MAP Target | Higher MAP Target | Lower MAP Target | Higher MAP Target |
n | 388 | 388 | 60 | 58 | 1,283 | 1,300 |
Baseline characteristics | ||||||
Age, yr | 65 (15) | 65 (13) | 66 (13) | 63 (13) | 75.3 (6.6) | 75.2 (6.9) |
Sex, male, n (%) | 250 (64.4) | 267 (68.8) | 31 (51.7) | 33 (56.9) | 696 (57.2) | 692 (55.9) |
Duration of vasopressor at randomization (min) | 216 (126) | 210 (132) | 540 (180–960) | 660 (300–1,020) | 186 (102–277) (n = 1,247) | 186 (104–284) (n = 1,262) |
Comorbidities | ||||||
Hypertension, n (%) | 173 (44.6) | 167 (43.0) | 34 (56.7) | 19 (32.8) | 590 (46.0) | 597 (46.0) (n = 1,299) |
Left ventricular failure, n (%) | 53 (13.7) | 59 (15.2) | 4 (6.7) | 6 (10.3) | 143 (11.1) | 143 (11.0) (n = 1,298) |
Cause(s) of vasodilatory hypotension, n (%) | Sepsis, 388 (100) | Sepsis, 388 (100) | Sepsis, 46 (76.7) | 37 (63.8) | Sepsis, 953 (78.4) | 964 (77.8) |
Pancreatitis, 3 (5.0) | 0 | Not sepsis, 263 (21.6) | 275 (22.2) | |||
Overdose, 1 (1.7) | 0 | (n = 1,216) | (n = 1,239) | |||
Pulmonary embolism, 2 (3.3) | 1 (1.7) | |||||
Burns, 1 (1.7) | 2 (3.4) | |||||
Other, 7 (11.7)a | 18 (31.0)b | |||||
Illness severity | ||||||
Sequential Organ Failure Assessment | 10.8 (3.1) | 10.7 (3.1) | — | — | — | — |
Simplified Acute Physiology Score II score | 57.2 (16.2) | 56.1 (15.5) | — | — | — | — |
Acute Physiology and Chronic Health Evaluation II | — | — | 24 (8) | 25 (6) | 20.9 (6.5) (n = 1,213) | 20.6 (6.1) (n = 1,239) |
MAP = mean arterial pressure.
Includes two patients in whom the admission diagnosis was unrelated to hypotension.
Includes 10 patients in whom the admission diagnosis was unrelated to hypotension.
Values are mean (sd) or median (interquartile range) as appropriate, unless otherwise specified. Dashes indicate data not reported.